<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04859322</url>
  </required_header>
  <id_info>
    <org_study_id>SIRG-2</org_study_id>
    <nct_id>NCT04859322</nct_id>
  </id_info>
  <brief_title>The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover</brief_title>
  <official_title>The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Malte Palm Suppli, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Section of Molecular Physiology, Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Metabolomics Core Facility, Department of Clinical, Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Biomedical Sciences &amp; NNF Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health, and Medical Sciences, University of Copenhagen, Copenhagen, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many patients with type 2 diabetes exhibit elevated plasma concentrations of the&#xD;
      glucose-mobilising pancreatic hormone glucagon; i.e. hyperglucagonaemia. This contributes to&#xD;
      the hyperglycaemic state of the patients and is considered an important component in the&#xD;
      pathophysiology of type 2 diabetes; but the mechanisms underlying this phenomenon remain&#xD;
      unclear. The liver constitutes the main target organ of glucagon, and studies have shown that&#xD;
      hyperglucagonaemia goes hand in hand with hyperaminoacidaemia and that both are associated&#xD;
      with non-alcoholic fatty liver disease (NAFLD), independently of the presence of type 2&#xD;
      diabetes. In line with this, several recent studies support the existence of a feedback-cycle&#xD;
      between the liver and the pancreatic alpha cells, governed by circulating glucagon and amino&#xD;
      acids. The investigators hypothesise that the presence of hepatic steatosis results in&#xD;
      hepatic glucagon resistance at the level of amino acid turnover, i.e. impaired&#xD;
      glucagon-induced suppression of circulating amino acid concentrations. If this hypothesis&#xD;
      proves correct, it would establish build-up of fat in the liver as a core mechanism&#xD;
      underlying hyperglucagonaemia and, since the hyperglucagonemia is at least partly responsible&#xD;
      for the fasting hyperglycaemia, as an important contributor to the hyperglycaemia of type 2&#xD;
      diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2021</start_date>
  <completion_date type="Anticipated">December 9, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 9, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nadir of the total amino acid concentration during a two-hour high physiological glucagon infusion during a pancreatic clamp with somatostatin</measure>
    <time_frame>depending on the nadir between time 60 minutes and time 180 minutes</time_frame>
    <description>micromol/liter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>average slope of the curve describing the change in the total amino acid concentration during 'supraphysiological' glucagon infusion</measure>
    <time_frame>between time 60 minutes and time 180 minutes</time_frame>
    <description>micromol/liter/minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the incremental area under the curve (iAUC) for total amino acid concentrations during 'supraphysiological' glucagon infusion</measure>
    <time_frame>between time 60 minutes and time 180 minutes</time_frame>
    <description>micromol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the percentage change in amino acid concentration during the last hour of the 'supraphysiological' glucagon infusion as assessed by baseline subtracted AUC</measure>
    <time_frame>between time 60 minutes and time 180 minutes</time_frame>
    <description>micromol/liter</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Glucagon Resistance</condition>
  <arm_group>
    <arm_group_label>Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 healthy participants included in the arm for 3 experimental days each. On each experimental day infusions of stable isotope glucose (0,6 micromol/kg/min), glucagon (1 hour low; 0,6 ng/kg/min, 2 hours high; 4,0 ng/kg/min), somatostatin (450 micrograms/hour) and insulin (0,1 mU/kg/min) will be administered. Between the first two experimental days the participants will follow a sedentary lifestyle combined with a high-calorie diet intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>Pancreatic clamp</description>
    <arm_group_label>Healthy Participants</arm_group_label>
    <other_name>Insulin</other_name>
    <other_name>Somatostatin</other_name>
    <other_name>6,6 H2-glucose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal fasting plasma glucose and glycated haemoglobin (HbA1c) &lt;42 mmol/mol&#xD;
&#xD;
          -  Body mass index (BMI) between 18.5 and 25 kg/m2&#xD;
&#xD;
          -  Haemoglobin &gt;8.3 mmol/l&#xD;
&#xD;
          -  Habitual diet in accordance with the Nordic Nutrition Recommendations&#xD;
&#xD;
          -  Age between 20 and 65 years&#xD;
&#xD;
          -  Oral and written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  First-degree relatives with diabetes&#xD;
&#xD;
          -  Fasting plasma triacylglycerol indicating dyslipidemia (≥2 mmol/l)&#xD;
&#xD;
          -  Nephropathy (estimated glomerular filtration rate (eGFR) &lt;60 ml/min and/or&#xD;
             microalbuminuria with an albumin to creatinine ratio of 30-300 μg/mg)&#xD;
&#xD;
          -  Known liver disease and/or alanine aminotransferase (ALT) and/or aspartate&#xD;
             aminotransferase (AST) &gt;2 × normal values&#xD;
&#xD;
          -  Signs of liver fibrosis and/or steatosis evaluated by FibroScan (CAP value &gt;2380 dB/m&#xD;
             and/or kPa &gt;65.0) and/or FIB-4 score (&gt;1.45)&#xD;
&#xD;
          -  &gt;5% steatosis evaluated by MRI carried out before experimental Day A (see Methods)&#xD;
&#xD;
          -  Use of medication&#xD;
&#xD;
          -  Use of dietary protein supplementation or any other dietary supplements that cannot be&#xD;
             paused during participation&#xD;
&#xD;
          -  Excessive training habits, defined as &gt;2 weekly strength and/or aerobic training&#xD;
             sessions&#xD;
&#xD;
          -  Pregnancy and/or breastfeeding&#xD;
&#xD;
          -  Implanted metal objects incompatible with magnetic resonance imaging (MRI)&#xD;
&#xD;
          -  Any condition that the investigator feels would interfere with trial completion&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Malte P Suppli, MD</last_name>
    <phone>25151436</phone>
    <email>malte.palm.suppli@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Clinical Metabolic Research</name>
      <address>
        <city>Hellerup</city>
        <state>Copenhagen</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malte P Suppli, MD</last_name>
      <phone>25151436</phone>
      <email>malte.palm.suppli@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Malte Palm Suppli, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

